Compare Incyte Corporation (INCY) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Redwire Corporation — how do they compare? Incyte Corporation trades at $120.67 (market cap $24.54B), while Redwire Corporation trades at $13.54 (market cap $3.38B). The key difference: Incyte Corporation is far larger — about 7.3× Redwire Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | RDW | |
|---|---|---|
Market Cap | $24.54B | $3.38B |
Sector | Health | Technology |
52-Week High | $129.93 | $25.90 |
52-Week Low | $81.61 | $5.06 |
Enterprise Value | $20.04B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Redwire (RDW) trades at $13.65, up 4.04% today, with strong technical momentum as moving averages signal bullish sentiment. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant net losses. Analyst consensus remains overwhelmingly positive with 80% buy ratings and a $17.50 price target, representing 28% upside potential from current levels.
While Redwire shows impressive revenue growth and defense contract momentum, investors face substantial risk from persistent losses, negative cash flow from operations, and high valuation multiples despite unprofitability. The company's pivot toward defense technology provides near-term stability but requires careful monitoring of margin improvement and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
